Stock Taper
SCREENER COMPARE ANY 2 STOCKS
AMRX
AMNEAL PHARMACEUTICALS, INC.
NASDAQ
$17.54
▼ DOWN 2.61% (-0.47)

KEY STATISTICS

Market Cap$5.60 B
52w High$19.26
52w Low$9.32
Dividend Yield—
Frequency—
P/E19.49
Volume1.15M
Shares Out.319.33M

COMPANY

LEADERSHIP

Chirag K. Patel
CHIEF EXECUTIVE
Chirag K. Patel

COMPENSATION 2026

Salary$800,000
Stock Awards$6,974,995
Incentive Plan Pay$848,000
All Other Comp.$68,750
Total$8,691,745

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 7, 2018
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
8,700

PRICE TARGET

Target High$25.00
Target Low$16.00
Target Median$19.00
Target Consensus$19.75

UPCOMING EARNINGS

DateOct 29, 2026
DayThursday
Rev. Est.$808.27M
OCT
29
THU

PRICE

$17.54 ▼ DOWN 2.61% (−$0.47)
$17.60$17.80$18.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM17.54

About Amneal Pharmaceuticals, Inc.

https://www.amneal.com ↗

Amneal Pharmaceuticals develops, manufactures, and markets generic and specialty drugs across various therapeutic areas through segments in generics, specialty, and government-focused distribution, serving global markets from New Jersey.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT AMNEAL PHARMACEUTICALS, INC. IS KNOWN FOR

CREXONT® (carbidopa and levodopa) extended-release capsules
CREXONT® (carbidopa and levodopa) extended-release capsules

Amneal's FDA-approved oral Parkinson's medication, launched in September 2024, uses a novel extended-release formulation to enhance symptom control duration and reduce dosing frequency, marking a major CNS treatment advancement and strategic focus.

COMPETITORS

COMPETITOR
ABBV COMPARE
JAZZ COMPARE
SUPN COMPARE
TEVA COMPARE
VTRS COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Specialty Segment— $420.21M — —
Amneal Specialty Pharma Segment$125.24M — $133.26M ▲$149.29M ▲

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
Specialty Segment$125.24M $275.23M ▲$133.26M ▼$149.29M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
200
LISTED HERE
26
RANKED BY POSITION SIZE
XAW.TO
0.00% · 10.5M
VTI
0.00% · 5.6M
XSMO
1.10% · 1.9M
SPSM
0.17% · 1.6M
DFAS
0.12% · 1.1M
SCHA
0.06% · 818.0K
FESM
0.20% · 748.6K
USVM
0.51% · 514.5K
FTXH
0.65% · 393.0K
CSMD
1.17% · 319.6K
ASCE
2.80% · 283.9K
BCUS
3.19% · 270.7K
PSC
0.17% · 259.4K
SRHQ
1.48% · 187.9K
XRSU.L
0.09% · 157.1K
GSSC
0.24% · 143.4K
EZM
0.16% · 87.5K
RSSL
0.10% · 81.5K
JHSC
0.12% · 50.2K
TQSM.TO
0.10% · 42.9K
BBSC
0.09% · 37.5K
SMOX
0.30% · 24.1K
IVSS
1.20% · 18.9K
ZSML.TO
0.17% · 16.7K
SEUS
0.03% · 15.7K
PILL
1.12% · 15.3K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
40.77%
HOLDERS
421
TOP 12 OF 421 · RANKED BY POSITION SIZE
Blackrock, Inc.
26.6M sh · $459.79M
Vanguard Group Inc
18.0M sh · $179.73M
Tpg Group Holdings (Sbs) Advisors, Inc.
16.2M sh · $86.58M
Rubric Capital Management LP
12.3M sh · $155.42M
Tpg Gp A, LLC
12.3M sh · $123.41M
Blackrock Inc.
11.3M sh · $71.64M
State Street Corp
7.4M sh · $127.35M
Citadel Advisors LLC
6.2M sh · $77.81M
Dimensional Fund Advisors LP
5.8M sh · $100.3M
Geode Capital Management, LLC
5.1M sh · $88.98M
Morgan Stanley
4.8M sh · $60.71M
Nantahala Capital Management, LLC
4.2M sh · $42.29M

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity5
Return On Assets4
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score3

TRADES BY CONGRESS

HOUSE TRADES
Josh Gottheimer
Josh Gottheimer
Sale (Full)
2019-05-24

INSIDER TRADES

★
OFFICER: EXECUTIVE VICE PRESIDENT
BOYER ANDREW S
Sale · 152.4K shares
2026-08-21
★
DIRECTOR
Kiely John
Sale · 50.0K shares
2026-08-13
★
DIRECTOR
Kiely John
Sale · 10.0K shares
2026-08-13
★
OFFICER: EVP, CHIEF LEGAL OFFICER
Daly Jason B.
Sale · 210.0K shares
2026-08-12

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 3
BUY 2
5 GRADES IN THE LAST 12 MONTHS
UBS BUY Barclays OVERWEIGHT Truist Securities BUY Piper Sandler OVERWEIGHT JP Morgan OVERWEIGHT

SECTORS PEERS

PEERPRICE
LNTH$100.77COMPARE
MIRM$97.46COMPARE
DYN$25.07COMPARE
NVST$27.13COMPARE
INDV$34.87COMPARE
TLX$11.29COMPARE
SUPN$43.73COMPARE
BHC$6.32COMPARE